<DOC>
	<DOCNO>NCT02616627</DOCNO>
	<brief_summary>Aims : 1 . To determine whether BMD muscle mass associate fracture adverse event dialysis patient . 2 . To explore effect interaction among FGF23 , calcium , phosphate , PTH vitamin D low bone mineral density sacropenia dialysis patient . Method : In study , investigator plan use DXA screen BMD , relevant novel bone microstructure parameter , body composition chronic dialysis patient . Also , investigator plan use blood testing measure blood level FGF23 , calcium , phosphate , PTH vitamin D. The investigator conduct prospectively follow program participant evaluate clinical course outcomes . Patients receive DXA ( include BMD body composition ) test blood work baseline one-year . Muscle power physical performance measure baseline , 6 month one-year .</brief_summary>
	<brief_title>Association Between DXA Results Complications , Clinical Courses Outcomes Chronic Dialysis Patients</brief_title>
	<detailed_description>Background : Several large-scale study enrol CKD patient discover low BMD still important risk factor develop fragility fracture , chronic dialysis patient report 4 to5 fold high risk fracture compare general population . However , relationship bone mineral density ( BMD ) dual-energy X-ray absorptiometry ( DXA ) fracture adverse event patient CKD patient still unclear . In addition , decline renal function could affect normal physiological regulating blood level calcium , phosphate , fibroblast growth factor 23 ( FGF23 ) , parathyroid hormone ( PTH ) , vitamin D , could influence bone mineral density chronic dialysis patient . Recently , well know serum FGF23 already elevate early stage CKD patient independently relate CKD . However , limited number report indicate effect interaction among FGF23 , calcium , phosphate , PTH vitamin D low bone mineral density sacropenia CKD patient . Aims : 1 . To determine whether BMD DXA associate fracture adverse event dialysis patient . 2 . To explore effect interaction among FGF23 , calcium , phosphate , PTH vitamin D low bone mineral density sacropenia dialysis patient . Method : In study , investigator plan use DXA screen BMD , relevant novel bone microstructure parameter , body composition chronic dialysis patient . Also , investigator plan use blood testing measure blood level FGF23 , calcium , phosphate , PTH vitamin D. The investigator conduct prospectively follow program participant evaluate clinical course outcomes . Patient characteristic Inclusion Criteria : 1 . Age &gt; 20 year one 2 . Chronic hemodialysis 3 . Chronic peritoneal dialysis Exclusion Criteria : get pregnant planning pregnancy Anticipated result : 1 . The investigator expect result finding discover study could show effect interaction FGF23 , calcium , phosphate , PTH vitamin D low bone mineral density sacropenia CKD patient , important step improve clinical decision osteoporosis fracture risk renal dialysis patient . 2 . Publishing result academic journal .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Patient characteristic 1 . Age &gt; 20 year one 2 . Chronic hemodialysis 3 . Chronic peritoneal dialysis 1. get pregnant planning pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>bone mineral density</keyword>
	<keyword>chronic dialysis</keyword>
	<keyword>end-stage renal disease</keyword>
	<keyword>body composition analysis</keyword>
	<keyword>sarcopenia</keyword>
</DOC>